232 related articles for article (PubMed ID: 24658583)
1. Overexpression of lymphoid enhancer-binding factor 1 (LEF1) in solid-pseudopapillary neoplasms of the pancreas.
Singhi AD; Lilo M; Hruban RH; Cressman KL; Fuhrer K; Seethala RR
Mod Pathol; 2014 Oct; 27(10):1355-63. PubMed ID: 24658583
[TBL] [Abstract][Full Text] [Related]
2. The usefulness of lymphoid enhancer-binding factor 1 and androgen receptor in diagnosing solid pseudopapillary neoplasm of the pancreas on cytopathology.
McHugh KE; Stelow EB; Harrison GP; Policarpio-Nicolas MLC
Cancer Cytopathol; 2019 Nov; 127(11):700-707. PubMed ID: 31584754
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostic Utility of LEF1 Immunostain in Cytology Specimens of Solid Pseudopapillary Neoplasm of Pancreas].
Farzaneh T; Nowroozizadeh B; Han M; Lee W
Acta Cytol; 2021; 65(3):250-256. PubMed ID: 33887729
[TBL] [Abstract][Full Text] [Related]
4. A limited panel of INSM1 and LEF1 immunostains accurately distinguishes between pancreatic neuroendocrine tumor and solid pseudopapillary neoplasm.
Guo W; Farzaneh T; Lee W; Nael A; Li X; Chandan VS
Pathol Res Pract; 2021 Jul; 223():153462. PubMed ID: 34048981
[TBL] [Abstract][Full Text] [Related]
5. Solid pseudopapillary neoplasms of the pancreas show an interruption of the Wnt-signaling pathway and express gene products of 11q.
Tiemann K; Heitling U; Kosmahl M; Klöppel G
Mod Pathol; 2007 Sep; 20(9):955-60. PubMed ID: 17632456
[TBL] [Abstract][Full Text] [Related]
6. TFE3 is a diagnostic marker for solid pseudopapillary neoplasms of the pancreas.
Jiang Y; Xie J; Wang B; Mu Y; Liu P
Hum Pathol; 2018 Nov; 81():166-175. PubMed ID: 30030118
[TBL] [Abstract][Full Text] [Related]
7. Lymphoid Enhancer Binding Factor 1 (LEF1) and Paired Box Gene 8 (PAX8): A Limited Immunohistochemistry Panel to Distinguish Solid Pseudopapillary Neoplasms and Pancreatic Neuroendocrine Tumors.
Lu H; Allende D; Liu X; Zhang Y
Appl Immunohistochem Mol Morphol; 2020; 28(10):776-780. PubMed ID: 32723981
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.
Ruz-Caracuel I; López-Janeiro Á; Heredia-Soto V; Ramón-Patino JL; Yébenes L; Berjón A; Hernández A; Gallego A; Ruiz P; Redondo A; Peláez-García A; Mendiola M; Hardisson D
Virchows Arch; 2021 Dec; 479(6):1167-1176. PubMed ID: 34420090
[TBL] [Abstract][Full Text] [Related]
9. Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas.
Tandon B; Peterson L; Gao J; Nelson B; Ma S; Rosen S; Chen YH
Mod Pathol; 2011 Nov; 24(11):1433-43. PubMed ID: 21685909
[TBL] [Abstract][Full Text] [Related]
10. Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways.
Cao D; Maitra A; Saavedra JA; Klimstra DS; Adsay NV; Hruban RH
Mod Pathol; 2005 Jun; 18(6):752-61. PubMed ID: 15696124
[TBL] [Abstract][Full Text] [Related]
11. Expression and colocalization of β-catenin and lymphoid enhancing factor-1 in prostate cancer progression.
Bauman TM; Vezina CM; Ricke EA; Halberg RB; Huang W; Peterson RE; Ricke WA
Hum Pathol; 2016 May; 51():124-33. PubMed ID: 27067790
[TBL] [Abstract][Full Text] [Related]
12. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations.
Abraham SC; Klimstra DS; Wilentz RE; Yeo CJ; Conlon K; Brennan M; Cameron JL; Wu TT; Hruban RH
Am J Pathol; 2002 Apr; 160(4):1361-9. PubMed ID: 11943721
[TBL] [Abstract][Full Text] [Related]
13. β-catenin (CTNNB1) mutation and LEF1 expression in sinonasal glomangiopericytoma (sinonasal-type hemangiopericytoma).
Suzuki Y; Ichihara S; Kawasaki T; Yanai H; Kitagawa S; Shimoyama Y; Nakamura S; Nakaguro M
Virchows Arch; 2018 Aug; 473(2):235-239. PubMed ID: 29736797
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological analysis of β-catenin and Axin-1 in solid pseudopapillary neoplasms of the pancreas.
Huang SC; Ng KF; Yeh TS; Chang HC; Su CY; Chen TC
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S438-46. PubMed ID: 21769465
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Utility of LEF1 Immunohistochemistry in Differentiating Deep Penetrating Nevi From Histologic Mimics.
Raghavan SS; Saleem A; Wang JY; Rieger KE; Brown RA; Novoa RA
Am J Surg Pathol; 2020 Oct; 44(10):1413-1418. PubMed ID: 32520758
[TBL] [Abstract][Full Text] [Related]
16. Paranuclear dot-like immunostaining for CD99: a unique staining pattern for diagnosing solid-pseudopapillary neoplasm of the pancreas.
Guo Y; Yuan F; Deng H; Wang HF; Jin XL; Xiao JC
Am J Surg Pathol; 2011 Jun; 35(6):799-806. PubMed ID: 21566515
[TBL] [Abstract][Full Text] [Related]
17. Loss of E-cadherin and cytoplasmic-nuclear expression of beta-catenin are the most useful immunoprofiles in the diagnosis of solid-pseudopapillary neoplasm of the pancreas.
Kim MJ; Jang SJ; Yu E
Hum Pathol; 2008 Feb; 39(2):251-8. PubMed ID: 17959228
[TBL] [Abstract][Full Text] [Related]
18. LEF1, TFE3, and AR are putative diagnostic markers of solid pseudopapillary neoplasms.
Kim EK; Jang M; Park M; Kim H
Oncotarget; 2017 Nov; 8(55):93404-93413. PubMed ID: 29212159
[TBL] [Abstract][Full Text] [Related]
19. Immunocytochemistry for SOX-11 and TFE3 as diagnostic markers for solid pseudopapillary neoplasms of the pancreas in FNA biopsies.
Foo WC; Harrison G; Zhang X
Cancer Cytopathol; 2017 Nov; 125(11):831-837. PubMed ID: 29045075
[TBL] [Abstract][Full Text] [Related]
20. "Pure" hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms.
Mattiolo P; Mafficini A; Lawlor RT; Marchegiani G; Malleo G; Pea A; Salvia R; Piccoli P; Sciammarella C; Santonicco N; Parisi A; Silvestris N; Milella M; Adsay V; Scarpa A; Luchini C
Virchows Arch; 2022 Jul; 481(1):41-47. PubMed ID: 35359182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
